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Abstract  
Background:  The implantable cardioverter defibrillator (ICD) is a life saving device for 
individuals with life threatening ventricular arrhythmias. There is no doubt that it is a cost 
effective therapy in various congenital and acquired arrhythmogenic disorders. Nevertheless, 
shock delivery may be painful and frightening which causes psychological distress and 
deterioration of perceived quality of life.                                                                                       
Methods: A systematic meta-analysis on studies reporting quality of life in patients implanted 
with ICDs was done using professional databases. Related articles and references of the relevant 
articles were also searched for suitable studies.                                                         
Results: Thirty studies with a total of 3412 patients on implantable defibrillators were identified. 
Five of them were large randomised studies with a total of 1680 patients, while 25 were non-
randomised studies. Medical Outcome Study 36-item Short Form health survey (SF – 36) was 
the most common instrument used for assessment of quality of life. Only one of the 5 major 
randomised trial reported worsening of quality of life after implantation of a defibrillator. In the 
subgroup of patients receiving shocks, three out of the five trials reported worsening of quality 
of   life.                                                                                    
Summary: Most of the randomised studies showed either neutral or better quality of life in 
patients on implantable defibrillators. In the subset of patients receiving shocks, worsening of 
quality of life was found in most randomised studies. Therefore, activation of antitachycardia 
pacing should be performed in every ICD-patient in order to miminze painful shocks and 
consequent deterioration of quality of life.                                                                         
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Introduction
            Implantable cardioverter - defibrillators (ICD) have proven their value as life saving 
devices1-3. As the number of patients implanted with these devices rises world-wide, concerns 
about the quality of the life prolonged by the ICDs become more and more relevant. Patients on 
ICD are prone for deterioration of quality of life (QOL) due to worsening of the pre-existing 
cardiac disorder as they survive longer with the support of the device. Unexpected and often 
painful shocks can either be perceived as instances of life regained or as potential threats to 
survival by different patients. Systematic attempts at evaluation of QOL in ICD recipients have 
been there over the past decade. This paper aims at a comprehensive analysis of the literature on 
QOL   in   ICD   recipients.                                                          
Methods
            A systematic accumulation of available data on QOL in patients with ICDs. PubMed 
searches were conducted using the search words implantable defibrillator, ICD, quality of life 
and QOL. The retrieved results were checked to identify relevant studies. Further studies were 
sought by searching for the related articles and the references of the retrieved article. Reports of 
major ICD trials were screened for data on quality of life.                                                       
Results
            Thirty studies on patients with ICDs reported data on QOL (Table 1)4-33. Of the total 
4653 patients in these 30 studies, 3412 had ICDs implanted. The earliest study in 1993 reported 
on 57 patients4. The largest available data is from the PainFREE Rx II trial with 634 patients on 
ICD33. The next largest study was the Antiarrhythmics Versus Implantable Defibrillators 
(AVID) trial with 416 patients on ICD with an equal number on amiodarone for comparison23. 
22 studies had 50 or more patients on ICD while only seven had over hundred patients on ICD. 
Fourteen studies were published in the last decade while sixteen were in the current decade. 
Twelve studies used Medical Outcome Study 36-item Short Form health survey (SF - 36) for 
assessment of quality of life. 
Instruments for Assessment of QOL                                                                     
            SF - 36 was the most common instrument used for QOL assessment across the studies. It 
comprises of a 36-item short-form questionnaire constructed to survey health status in the 
Medical Outcomes Study33.  SF - 36 is a generic instrument and not disease specific. There are 
eight multi-item scales, four each for physical and mental health assessment. The physical scales 
are: 1) Physical functioning, 2) Role physical, 3) Bodily pain and 4) General health. The scales 
for assessing mental health are: 1) Vitality, 2) Social functioning, 3) Role emotional and 4) 
Mental   health.                                                            
            Various other scales have also been used in the studies, like Ferrans and Powers Quality 
of Life Index7,18,30, Quality-of-life Profile for the Chronically Ill13, Quality of Life Index: 
Cardiac Version1 and specifically developed quality of life questionnaire for ICD patients10. The 
latter two can be considered as disease specific measurements of QOL.                                   
Major   Randomized   Trials                                                                          
            Of the thirty studies available, five were large randomized trials (Table 2) with 1680 
patients on ICD altogether. Three of them were primary prevention trials17,27,33 while two of 
them were secondary prevention trials21,23. One primary prevention trial reported worsening of 
QOL after ICD while another reported neutral results and the third and most recent one reported 
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improvement in QOL. This disparity was present among the secondary prevention trials as well, 
where one reported improvement while another reported worsening of QOL. Disparity was less 
between the trials in those patients receiving ICD shocks. Three trials reported worsening of 
QOL while one each reported neutral and better QOL in patients receiving shocks.
Table 1: ICD Studies reporting Quality of Life Data
Table 2: Randomized ICD Trials Reporting Quality of Life
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Summary of QOL Data from Major Randomized Trials                                           
A] Primary Prevention Trials                                                                                 
1. CABG Patch Trial                                                                                           
               Patients   with   impaired   left   ventricular   function   and   positive   signal   averaged 
electrocardiogram undergoing CABG were randomly assigned to ICD versus no antiarrhythmic 
treatment in the CABG Patch trial17. All ICD-patients were implanted with patch electrodes 
during thoracotomy for CABG application. SF-36 was used to evaluate the QOL in 490 (68%) 
of the 719 patients available at 6 month follow up. Of these, 262 patients had ICD while 228 
were controls. Patients in the ICD group had lower levels of psychological well being than the 
control group, especially those who experienced shock delivery of the ICD. The study was 
terminated when statistical analysis suggested that there was no significant difference in the 
primary outcome of total mortality. The lack of effect of ICDs in reducing mortality has been 
attributed to better survival in patients who have undergone revascularisation by CABG.      
2.   AMIOVIRT   Trial                                                                          
            Amiodarone versus implantable cardioverter-defibrillator (AMIOVIRT) trial included 
one hundred three patients with non-ischemic dilated cardiomyopathy (NIDCM), left ventricular 
ejection fraction < or = 0.35, and asymptomatic non sustained ventricular tachycardia (NSVT)27. 
They were randomized to receive either amiodarone or an ICD. The authors described no 
statistically significant survival advantage after one year or three years. QOL was also similar in 
both treatment groups. This trial was also neutral towards change of QOL in those receiving 
ICD shocks. Quality of Well Being Schedule and the State Trait Anxiety Inventory were the 
instruments   used   for   assessment   in   this   study.                                                
3. PainFREE Rx II Trial                                                                                         
            Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial 
was the largest trial reporting data on QOL as well as the latest33. This trial compared the safety 
and  utility   of   empirical   anti-tachycardia   pacing  (ATP)   with   shocks   for   fast  ventricular 
tachycardia in patients receiving ICD. Of 634 ICD patients 313 were randomized to empirical 
ATP while 321 patients received shocks as the initial therapy of spontaneous fast ventricular 
tachycardia. ATP was effective in 229 of 284 episodes in the ATP arm. QOL was measured with 
the SF-36 and found to be improved in patients with fast ventricular tachycardia in both arms 
but even more in the ATP arm. Of the 131 patients with fast ventricular tachycardia, 98 
completed SF-36 both at baseline and at 1 year. The ATP arm had significant improvement in 5 
subscales - physical functioning, role physical, bodily pain, social functioning and role 
emotional, while the shock arm had improvement in only bodily pain score. None of the 
subscale measurements were significantly reduced at 1 year in either arm.                      
B]   Secondary   Prevention   Trials                                                            
1. The Canadian Implantable Defibrillator Study (CIDS)                                      
               CIDS21  compared antiarrhythmic therapy versus ICD in patients resuscitated from 
cardiac arrest, and those with sustained ventricular tachycardia with syncope or ventricular 
tachycardia of more than 150 beats per minute with near syncope and left ventricular ejection 
fraction   <   or   =   0.35   or   syncope   with   inducible   ventricular   tachycardia.
               The total mortality was lower in the ICD group, but the difference did not reach 
statistical significance. (P=0.09). QOL evaluation was done as a secondary endpoint in the study 
with the Rand Corporation's 38-item Mental Health Inventory (MHI) and the Nottingham Health 
Profile (NHP) for 317 English-speaking participants.  Perceived QOL was found to be improved 
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more in the ICD group. Significant improvement from baseline to the 6- and 12-month follow-
up assessment was seen for 7 of the 10 variables assessed. Quality of life did not improve in 
those patients who received > or =5 shocks from their device. Still they were comparable to the 
antiarrhythmic group in QOL. There was no difference between those who received no shock 
and those who received 1-4 shocks from their ICD. None of the quality-of-life variables 
improved with time in the antiarrhythmic therapy group.                                             
2. The Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial                         
            AVID Trial1 compared antiarrhythmic drug therapy with ICD in survivors of cardiac 
arrest and those with sustained ventricular tachycardia with syncope, or hemodynamically 
unstable sustained ventricular tachycardia with ejection fraction < or = 40%. The study was 
prematurely terminated when a statistically significant reduction in mortality was demonstrated 
in the ICD group. Perceived QOL was evaluated as a secondary endpoint using SF-36 and 
Quality of Life Index: Cardiac Version. Of the 800 eligible patients with a 1-year survival, 416 
patients were in the ICD group and 384 patients in the antiarrhythmic group. Perceived QOL 
related was low in both groups, related to adverse symptoms of the particular therapy. The 
occurrence of one or more shocks was associated with significant reduction in QOL in the ICD 
group.  
Data   from   non-randomised   studies                                                                
        Of the 30 studies evaluated in this report, 25 were non-randomised (Table 3). Sixteen of 
these trials had 50 or more patients on ICD. Five of these trials reported improvement in QOL in 
ICD patients while 6 reported neutral results and five reported worsening of QOL. IICD 
implantation did not worsen QOL in recipients. 
Table 3: Quality of Life in Major Non Randomised Studies
            The earliest study which reported QOL data from ICD patients was by Luderitz et al4. 
Fifty-five of their 57 patients stated that it was worth having an ICD implanted. This study also 
documented that patients receiving more than 5 shocks had a higher anxiety level. The latest of 
the non-randomised studies was by Sears et al32. They noted that patients with high positive 
health expectations and high optimism reported better mental health and social functioning at 
follow-up assessment. These two factors may be targeted in future studies to improve QOL in 
ICD   recipients.                                                                          
               The  largest  of  the non-randomised studies actually reported  on  dual  chamber 
defibrillators for restoration of sinus rhythm in atrial tachyarrhythmias. This study by Newman 
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et al25 had 267 patients implanted with DDD ICD. A total of 150 patients completed SF-36 
evaluation. Significant improvement was noted in role-physical, physical functioning, vitality, 
mental health and social functioning scales. No deterioration of QOL was noted in those who 
received   shocks.                                                                                          
            In the next largest non-randomized study by Kamphuis et al22 133 patients were on ICD 
and 35 on other modalities of treatment. No significant difference in QOL was noted between 
the two groups. Physical function, mental health and social function improved with time in both 
treatment groups. In contrast, Stankoweit et al15 who studied 132 patients on ICD noted reduced 
well   being   in   61%   of   them.                                                                            
Conclusion
               Distressing aspects of ICD shocks are lack of warning, multiple shocks, and 
progressively increased sensations with multiple shocks. Three of the major randomised studies 
reported worsening of QOL in those patients receiving ICD shocks, especially when  patients 
were receiving five or more shocks. Despite the AMIOVIRT Trial27 did not find any difference 
in the QOL between those receiving ICD shocks, the main issue regarding quality of life is the 
occurrence of shocks. The PainFREE Rx II Trial33 demonstrates very clearly that QOL can be 
improved by programming of antitachycardia pacing even in patients with fast VTs. This trial 
also documented the efficacy of antitachycardia pacing.                                           
            With regard to a potential deterioration of perceived QOL caused by delivery of ICD 
shocks for fast VTs, we would recommend to program ATP attempts in all ICD patients 
regardless of the cycle length of the index arrhythmia.                                                                   
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